Condition: Esophageal Squamous Cell Carcinoma (ESCC) · Locally Advanced Unresectable Esophageal Cancer · Sponsor: Ming-Yu Lien
This is a Phase II, open-label, single-arm, multicenter study evaluating the safety and efficacy of combining Tislelizumab with induction chemoradiotherapy (CRT), followed by conversion surgery, in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC). Patients will receive induction CRT with weekly paclitaxel and cisplatin along with Tislelizumab, followed by two cycles of consolidation Tislelizumab-chemotherapy. If the tumor becomes resectable, patients will undergo surgery. The primary goal is to assess the 2-year overall survival (OS) rate. Secondary outcomes include pathological complete response (pCR), conversion rate, R0 resection rate, disease-free survival (DFS), recurrence-free survival (RFS), and treatment-related adverse events.
This description comes directly from the study's public registry record.
Ming-Yu Lein, MD · 0975680832 · leinmirain@hotmail.com
Always discuss trial participation with your own doctor first.
| Kaohsiung Chang Gung Memorial Hospital | Kaohsiung City, Taiwan | Not Yet Recruiting |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City, Taiwan | Not Yet Recruiting |
| China Medical University Hospital | Taichung, Taiwan | Recruiting |
| Taichung Veterans General Hospital | Taichung, Taiwan | Not Yet Recruiting |
| National Cheng Kung University Hospital | Tainan, Taiwan | Not Yet Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Not Yet Recruiting |
| Taipei Veterans General Hospital | Taipei, Taiwan | Not Yet Recruiting |
| Linkou Chang Gung Memorial Hospital | Taoyuan, Taiwan | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07039162